FN1 and cancer: This antibody was widely used thereafter by different groups, and has allowed all of the early extensive immunohistochemical studies that have clearly established the outstanding presence of B-FN in different kinds of pathologies, including cancer and all angiogenesis-associated pathologies [12], [13], that B-FN is an excellent marker of angiogenesis [13], [14] and that the mAb BC1 could be used to selectively target cancer in vivo[15].